Federated Hermes, Inc. Contrafect Corp Transaction History

Federated Hermes, Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 13, 2021	BUY	$4.46 - $6.68 $8.92 Million - $13.4 Million	2,000,000 Added 37.76%	7,297,188 $35 Million
Q2 2020 Aug 13, 2020	BUY	$4.69 - $7.81 $10.5 Million - $17.6 Million	2,247,188 Added 73.68%	5,297,188 $33.8 Million
Q1 2020 May 13, 2020	BUY	$5.5 - $12.3 $16.8 Million - $37.5 Million	3,050,000 New	3,050,000 $17.6 Million

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.